Nanotechnology Now





Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Leading nanomedicine firm Nanobiotix successfully closes its $ 11 million series-C financing round

Abstract:
Nanobiotix, based in Paris, France, announces the closing of a $ 11 million series-C financing round. The company develops innovative therapeutic products for cancer using nanotechnologies.

Leading nanomedicine firm Nanobiotix successfully closes its $ 11 million series-C financing round

Paris | Posted on May 3rd, 2010

Nanobiotix raised US 11 million from a strong new and existing syndicate of investors. CIC Vizille Capital Innovation has led this new round with Masseran Gestion. Existing shareholder have strongly participated in the round, Matignon Technologies, OTC Asset Management, Cap Decisif Management, and Amorçage Rhône-Alpes.

"This successful closing is the recognition of the value of Nanobiotix breakthrough technology NanoXray. This financing will enable us to continue to advance our lead programs through clinical studies. We first plan on reinforcing our scientific /developpement team and resources: we are entering our first-in-man clinical study of nanoXray therapeutics with IGR Institut Gustave Roussy, - a Europe leading cancer treatment center - for Soft Tissue Sarcoma as initial indication. First preclinical data are very promising: safety in animals of NBTXR3 - when activated by ionizing radiation has been demonstrated; performance has clearly shown the potential of this product to become a new approach for cancer treatment," says Dr Laurent Levy, PhD, co-founder and CEO of Nanobiotix, a worldwide pioneer in nanomedicine.

"We are thrilled to be part of this very exciting adventure and pleased to help accelerate the development of a new class of cancer treatment, more effective and less deadly to healthy tissues. Nanobiotix has mastered the critical issues related to NanoXray reproductibility, scalability and stability," says Karine Lignel; CIC - Vizille Capital Innovation.

Since its creation in 2003, the company has made tremendous progresses and obtained significant results. It has a well balanced pipeline and a unique nanomedicine expertise in developing a very promising therapy for cancer treatment.

"We are confident in the development of Nanobiotix and its technology. We truly believe that is the best risk reward products in biotech field," says Jerome Snollaerts; Cap Decisif Management.

In parallel to the ongoing clinical developments, Nanobiotix has built an industrial and academic collaborative projects portfolio including research programs and industrial partnering, like Sonodrug with Philips Research or Biotech Corp in Malaysia.

"This is a significant step to the development of nanoXRay and we are excited to be that close to offer a potential alternative to patients," Patrick Langlois; Chairman of the non executive board.

####

About Nanobiotix
Nanobiotix is a leading nanomedicine company combining dramatic advances in nanotechnology and molecular biology to develop "nanoXray a technology platform that is expected to be turned 'on' and 'off' outside the body to selectively treat a variety of cancers safely and noninvasively. Use of nanoXray is intended to resolve radiation therapy's biggest drawback: destruction of healthy tissue and its subsequent deleterious side effects when a high dose of Xray is necessary. After nanoXray nanoparticles accumulate in the target tissues, a standard X-ray is applied that is intended to generate a local therapeutic effect, designed to destroy only the targeted tumor cells. This mechanism suggests total control of the intended therapeutic effect.

About NanoXray Platform
NanoXray therapeutic platform is designed to enable the precise destruction of cancer cells made possible by the controlled application of an outside the body energy source, in that case an X-ray. The nanoparticles that comprise the nanoXray platform allow for an extensive combination of therapeutic modalities and malignant pathologies. Nbtxr3, the first product to be developed from the nanoXray pipeline, also is the first-in-class product to be activated by radiotherapy. The intended initial indications for Nbtxr3 are:

Soft Tissue Sarcoma - Hepatic Cancer - Colon cancer - Lung cancer - Pancreatic cancer

Dr Laurent Levy will be attending BIO Chicago, from May 3 to May 6.

For more information, please click here

Contacts:
60 rue de Wattignies
Bat B 3rd floor
75012 Paris, France

Tel : + 33 (0) 1 40 26 04 70
Fax : +33 (0) 1 40 26 04 44

Copyright © Business Wire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Possible Futures

Global Carbon Nanotubes (CNT) Market Expected To Reach USD 3.42 Billion By 2022 May 29th, 2015

Global Nano-Enabled Packaging Market For Food and Beverages Will Reach $15.0 billion in 2020 May 26th, 2015

Simulations predict flat liquid May 21st, 2015

Nature inspires first artificial molecular pump: Simple design mimics pumping mechanism of life-sustaining proteins found in living cells May 19th, 2015

Investments/IPO's/Splits

Arrowhead to Present at Jefferies 2015 Healthcare Conference May 27th, 2015

Evident Thermoelectrics Acquires GMZ Energy: Investment Accelerates Launch Of Evident's Thermoelectric Modules For Waste Heat May 20th, 2015

Nanometrics Announces Live Webcast of Upcoming Investor and Analyst Day May 20th, 2015

PEN Inc. Announces First Quarter Financial Results: Investor Webcast and Business Update Set for May 21, 1 pm EDT May 13th, 2015

Nanomedicine

New chip makes testing for antibiotic-resistant bacteria faster, easier: Researchers at the University of Toronto design diagnostic chip to reduce testing time from days to one hour, allowing doctors to pick the right antibiotic the first time May 28th, 2015

Arrowhead to Present at Jefferies 2015 Healthcare Conference May 27th, 2015

Seeing the action: UCSB researchers develop a novel device to image the minute forces and actions involved in cell membrane hemifusion May 27th, 2015

Nanotechnology identifies brain tumor types through MRI 'virtual biopsy' in animal studies: If results are confirmed in humans, tumor cells could someday be diagnosed by MRI imaging and treated with tumor-specific IV injections; new NIH grant will fund future study May 27th, 2015

Announcements

OSU researchers prove magnetism can control heat, sound: Team leverages OSC services to help confirm, interpret experimental findings May 29th, 2015

Two UCSB Professors Receive Early Career Research Awards: The Department of Energys award for young scientists acknowledges UC Santa Barbaras standing as a top tier research institution May 29th, 2015

Global Carbon Nanotubes (CNT) Market Expected To Reach USD 3.42 Billion By 2022 May 29th, 2015

New chip makes testing for antibiotic-resistant bacteria faster, easier: Researchers at the University of Toronto design diagnostic chip to reduce testing time from days to one hour, allowing doctors to pick the right antibiotic the first time May 28th, 2015

Nanobiotechnology

New technique speeds nanoMRI imaging: Multiplexing technique for nanoscale magnetic resonance imaging developed by researchers in Switzerland cuts normal scan time from two weeks to two days May 28th, 2015

Seeing the action: UCSB researchers develop a novel device to image the minute forces and actions involved in cell membrane hemifusion May 27th, 2015

Nanotechnology identifies brain tumor types through MRI 'virtual biopsy' in animal studies: If results are confirmed in humans, tumor cells could someday be diagnosed by MRI imaging and treated with tumor-specific IV injections; new NIH grant will fund future study May 27th, 2015

Who needs water to assemble DNA? Non-aqueous solvent supports DNA nanotechnology May 27th, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project